I reported in late June that Danish researchers had made a most curious discovery of divergent rates of suspected adverse effects (SAEs) between batches of the Pfizer-BioNTech mRNA injections administered in their country.
Via European Journal of Clinical Investigation (emphasis added):
Vaccination has been widely implemented for mitigation of coronavirus disease-2019 (Covid-19), and by 11 November 2022, 701 million doses of the BNT162b2 mRNA vaccine (Pfizer-BioNTech) had been administered and linked with 971,021 reports of suspected adverse effects (SAEs) in the European Union/European Economic Area (EU/EEA).1 Vaccine vials with individual doses are supplied in batches with stringent quality control to ensure batch and dose uniformity.2 Clinical data on individual vaccine batch levels have not been reported and batch-dependent variation in the clinical efficacy and safety of authorized vaccines would appear to be highly unlikely. However, not least in view of the emergency use market authorization and rapid implementation of large-scale vaccination programs, the possibility of batch-dependent variation appears worthy of investigation. We therefore examined rates of SAEs between different BNT162b2 vaccine batches administered in Denmark (population 5.8 million) from 27 December 2020 to 11 January 2022…
The observed variation in SAE [severe adverse event] rates and seriousness between BTN162b2 vaccine batches in this nationwide study was contrary to the expected homogenous rate and distribution of SAEs between batches.
In conclusion, the results suggest the existence of a batch-dependent safety signal for the BNT162b2 vaccine, and more studies are warranted to explore this preliminary observation and its consequences.
No explanation for this anomaly from Pfizer has been forthcoming.
Now, in a separate instance, Pfizer is admitting to distributing different batches to different groups.
Via NTD News (emphasis added):
According to two executives at Pfizer Inc., Australia-based staff at the pharmaceutical company were provided with their own separate batch of specially imported COVID-19 vaccines. The executives spoke at a hearing in the Australian Senate, where they were questioned by Queensland Senator Malcolm Roberts.
An excerpt from the hearing was subsequently shared by Mr. Roberts on his YouTube channel. The shared segment depicts the Pfizer representatives—Dr. Krishan Thiru, Medical Director for Pfizer Australia and New Zealand, and the company’s Head of Regulatory Sciences, Dr. Brian Hewitt—fielding the senator’s questions.
The excuse offered by the Pfizer operatives, which strains credulity, is that the private, select batch of vaccines reserved for Pfizer employees was necessary to not subtract from the Australian government’s supply for the general population.
If Pfizer did this in Australia, it may have followed the same practice in the United States. The GOP House should be all over this. Subpoenas need to fly. The possibility of special set-aside shots for Pfizer employees, and for what reason, must be investigated.